Insider Transactions in Q3 2024 at Phreesia, Inc. (PHR)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
24
-0.27%
|
$576
$24.04 P/Share
|
|
Sep 18
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
61
-0.67%
|
$1,464
$24.09 P/Share
|
|
Sep 17
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
36
-0.4%
|
$864
$24.77 P/Share
|
|
Sep 12
2024
|
Lisa Egbuonu Davis Director |
SELL
Open market or private sale
|
Direct |
1,400
-7.17%
|
$32,200
$23.03 P/Share
|
|
Sep 11
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,072
-1.68%
|
$47,656
$23.36 P/Share
|
|
Sep 10
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,295
-0.43%
|
$121,785
$23.25 P/Share
|
|
Sep 10
2024
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
744
-2.42%
|
$17,112
$23.25 P/Share
|
|
Sep 10
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,502
-3.43%
|
$80,546
$23.25 P/Share
|
|
Sep 10
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,148
-0.41%
|
$72,404
$23.25 P/Share
|
|
Sep 10
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Indirect |
95
-1.03%
|
$2,185
$23.25 P/Share
|
|
Sep 10
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,716
-0.84%
|
$39,468
$23.25 P/Share
|
|
Sep 10
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
2,622
-2.09%
|
$60,306
$23.25 P/Share
|
|
Sep 10
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
737
-0.61%
|
$16,951
$23.25 P/Share
|
|
Sep 06
2024
|
Allison C Hoffman General Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
4,694
+3.6%
|
-
|
|
Sep 06
2024
|
Balaji Gandhi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,633
+5.23%
|
-
|
|
Sep 06
2024
|
Chaim Indig Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,670
+0.78%
|
-
|
|
Sep 06
2024
|
Yvonne Hui Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,049
+6.24%
|
-
|
|
Sep 06
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Indirect |
234
+2.48%
|
-
|
|
Sep 06
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
2,816
+1.35%
|
-
|
|
Sep 06
2024
|
Evan Roberts Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,633
+0.74%
|
-
|
|
Sep 06
2024
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
1,642
+1.35%
|
-
|
|
Aug 26
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
14,110
-10.44%
|
$366,860
$26.03 P/Share
|
|
Aug 15
2024
|
David Linetsky SVP, Life Sciences |
BUY
Grant, award, or other acquisition
|
Indirect |
2,000
+18.26%
|
-
|
|
Jul 31
2024
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
400
+0.98%
|
$9,600
$24.95 P/Share
|
|
Jul 31
2024
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
400
+0.85%
|
$9,600
$24.95 P/Share
|
|
Jul 31
2024
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
400
+1.09%
|
$9,600
$24.95 P/Share
|
|
Jul 29
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7
-0.0%
|
$168
$24.75 P/Share
|
|
Jul 29
2024
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7
+0.0%
|
$14
$2.03 P/Share
|
|
Jul 18
2024
|
Mark Douglas Smith Director |
SELL
Open market or private sale
|
Direct |
7,000
-18.59%
|
$175,000
$25.0 P/Share
|
|
Jul 18
2024
|
Mark Douglas Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+15.68%
|
$28,000
$4.71 P/Share
|
|
Jul 16
2024
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,644
-0.22%
|
$60,812
$23.74 P/Share
|
|
Jul 16
2024
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,820
-0.89%
|
$41,860
$23.74 P/Share
|
|
Jul 16
2024
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,669
-0.22%
|
$38,387
$23.74 P/Share
|
|
Jul 16
2024
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
374
-0.31%
|
$8,602
$23.74 P/Share
|
|
Jul 16
2024
|
Balaji Gandhi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
783
-0.81%
|
$18,009
$23.74 P/Share
|
|
Jul 16
2024
|
Allison C Hoffman General Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
800
-0.59%
|
$18,400
$23.74 P/Share
|
|
Jul 16
2024
|
Yvonne Hui Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
283
-0.98%
|
$6,509
$23.74 P/Share
|
|
Jul 15
2024
|
Yvonne Hui Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+30.95%
|
$286,000
$22.82 P/Share
|